home / stock / apm / apm news

APM News and Press, Aptorum Group Limited From 03/30/20

Stock Information
Company Name: Aptorum Group Limited
Stock Symbol: APM
Market: NASDAQ
Website: aptorumgroup.com
Menu
APM APM Quote APM Short APM News APM Articles APM Message Board
Get APM Alerts

News, Short Squeeze, Breakout and More Instantly...
APM - Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today provides an update on the Company’s operations in light of the recent declaration of the corona...
APM - Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT(TM) Platform and Acticule Infectious Disease Platform

Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease areas, today announced that it is initiating an additional research and dev...

APM - Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference

Aptorum Group Limited (NASDAQ:APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced that Ian Huen, Chief Executive Officer and Executive Director, and Darren Lui, President and ...

APM - Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies

NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and April 2, 2020, featuring leading companies from the life sciences indus...
APM - Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants

Aptorum Group Limited (NASDAQ:APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the closing of a registered direct offering of 1,351,350 Class A ordinary shares at a per sha...

APM - Aptorum Group Announces Pricing of $10 Million Registered Direct Offering

Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the pricing of a registered direct offering of 1,351,350 Class A ordinary shares and warrant...

APM - Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong

Aptorum Group Limited (“Aptorum Group”), a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the commercialization of its dietary supplement for women undergoing menopause and experiencing related symptoms. T...
APM - Aptorum Group (APM) Investor Presentation - Slideshow

The following slide deck was published by Aptorum Group Limited in conjunction with this Read more ...

APM - Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020

Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces further positive data from its current investigational new drug (IND)-enabling studies for ALS-4, ...

APM - Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces positive data and development in relation to its repurposed drug candidate, SACT-1, for the treatm...
Previous 10 Next 10